Remicade Ulcerative Colitis Indication Expands To Maintenance Therapy
This article was originally published in The Pink Sheet Daily
Remicade becomes the only biologic indicated for inducing and maintaining clinical remission of ulcerative colitis and Crohn’s disease, according to Centocor.
You may also be interested in...
J&J subsidiary also anticipates eventually using the sales force for another psoriasis product it has in its pipeline.
Remicade becomes the first biologic approved for ulcerative colitis following a priority review, J&J subsidiary Centocor says.
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.